LHRH-conjugated lytic peptides directly target prostate cancer cells

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 104-110

  Yates, Clayton ^a   Sharp, Starlette ^a   Jones, Jacqueline ^a   Topps, Daphne ^a   Coleman, Mathew ^a   Aneja, Ritu ^b   Jaynes, Jesse ^a   Turner, Timothy ^a  

^a TUSKEGEE UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Luteinizing hormone releasing hormone; Luteinizing hormone releasing hormone receptors; Lytic peptides; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN ASSOCIATED PEPTIDE DERIVATIVE; GONADORELIN CONJUGATE JC21 PEPTIDE; GONADORELIN CONJUGATE JCH PEPTIDE; GONADORELIN RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; COCULTURE; CONCENTRATION (PARAMETERS); CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; STROMA CELL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 78549244732     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.015     Document Type: Article

References (35)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Society AC Cancer Facts & Figures 2009 2009, American Cancer Society.
3. Society AC Cancer Facts & Figures for African Americans 2009-2010 2009, American Cancer Society.
4. Bennett C.L., Price D.K., Kim S., Liu D., Jovanovic B.D., Nathan D., et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 2002, 20:3599-3604.
5. Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937-1940.
6. Hansel W., Leuschner C., Enright F. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007, 269:26-33.
7. Leuschner C., Enright F.M., Gawronska-Kozak B., Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003, 56:239-249.
8. Ballweber L.M., Jaynes J.E., Stamm W.E., Lampe M.F. In vitro microbicidal activities of cecropin peptides D2A21 and D4E1 and gel formulations containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother 2002, 46:34-41.
9. Jaynes J.M., Julian G.R., Jeffers G.W., White K.L., Enright F.M. In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines. Pept Res 1989, 2:157-160.
10. Jaynes J.M., Burton C.A., Barr S.C., Jeffers G.W., Julian G.R., White K.L., et al. In vitro cytocidal effects of novel lytic peptides on Plasmodium falciparum and Trypanosoma cruzi. FASEB J 1988, 2:2878-2883.
11. Jaynes J.M., Julian G.R., Jeffers G.W., White K.L., Enright F.M. In vitro cytocidal effect lytic peptides on several transformed mammalian cell lines. Pept Res 1989, 2:157-160.
12. Thwaini A., Naase M., Chinegwundoh F., Baithun S., Ghali L., Shergill I., et al. Gonadotropins and prostate cancer: revisited. Urol Int 2006, 77:289-296.
13. Boman H.G. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995, 13:61-92.
14. Qayum A., Gullick W., Clayton R.C., Sikora K., Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990, 62:96-99.
15. Qayum A., Gullick W.J., Waxman J. Gonadotrophin-releasing hormone: physiological significance and relevance to cancer. Prog Growth Factor Res 1991, 3:115-130.
16. Platz E.A., Pollak M.N., Rimm E.B., Majeed N., Tao Y., Willett W.C., et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999, 8:1107-1110.
17. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978, 21:274-281.
18. Dondi D., Moretti R.M., Montagnani Marelli M., Pratesi G., Polizzi D., Milani M., et al. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 1998, 76:506-511.
19. Jungwirth A., Pinski J., Galvan G., Halmos G., Szepeshazi K., Cai R.Z., et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997, 33:1141-1148.
20. Turner T., Chen P., Goodly L.J., Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metast 1996, 14:409-418.
21. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23.
22. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980, 37:115-132.
23. Yates C., Shepard C.R., Papworth G., Dash A., Beer Stolz D., Tannenbaum S., et al. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res 2007, 97:225-246.
24. Yates C.C., Shepard C.R., Stolz D.B., Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007, 96:1246-1252.
25. Arlotti J.A., Cimino T.S., Nguyen T., Dhir R., Thomas A., Jaynes J.M., et al. Efficacy of a synthetic lytic peptide in the treatment of prostate cancer. Urol Oncol 2001, 6:97-102.
26. Bodek G., Kowalczyk A., Waclawik A., Huhtaniemi I., Ziecik A.J. Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway. Exp Biol Med (Maywood) 2005, 230:421-428.
27. Halmos G., Arencibia J.M., Schally A.V., Davis R., Bostwick D.G. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000, 163:623-629.
28. Leuschner C., Hansel W. Targeting breast and prostate cancers through their hormone receptors. Biol Reprod 2005, 73:860-865.
29. Chalekson C.P., Neumeister M.W., Jaynes J. Treatment of infected wounds with the antimicrobial peptide D2A21. J Trauma 2003, 54:770-774.
30. Robertson C.N., Roberson K.M., Pinero A., Jaynes J.M., Paulson D.F. Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. World J Urol 1998, 16:405-409.
31. Josson S., Sharp S., Aneja R., Wang R., Turner T., Chung L., et al. Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. J Onocol 2010, 2010:10.
32. Sung S.Y., Hsieh C.L., Law A., Zhau H.E., Pathak S., Multani A.S., et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 2008, 68:9996-10003.
33. Hansel W., Leuschner C., Gawronska B., Enright F. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates. Reprod Biol 2001, 1:20-32.
34. Hansel W., Enright F., Leuschner C. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol Cell Endocrinol 2007, 260-262:183-189.
35. Leuschner C., Enright F.M., Gawronska B., Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003, 78:17-27.